New and classic insights into presumed ocular histoplasmosis syndrome and its treatment

Current Opinion in Ophthalmology

Volumn 16, Issue 3, 2005, Pages 160-165

  Oliver, Alejandro ^a   Ciulla, Thomas A ^b   Comer, Grant M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MIDWEST EYE INSTITUTE   (United States)

Author keywords

Choroidal neovascularization; Photodynamic therapy; Presumed ocular histoplasmosis syndrome; Submacular surgery

Indexed keywords

ANECORTAVE; ANTIFUNGAL AGENT; BENZOPORPHYRIN DERIVATIVE; CORTICOSTEROID; MONOCLONAL ANTIBODY; PEGAPTANIB; PREDNISONE; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN;

CATARACT; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; HISTOPLASMOSIS; HUMAN; INTRAOCULAR HYPERTENSION; LASER COAGULATION; NONHUMAN; OCULAR HISTOPLASMOSIS; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME;

CHOROIDAL NEOVASCULARIZATION; EYE INFECTIONS, FUNGAL; HISTOPLASMOSIS; HUMANS; OPHTHALMOLOGIC SURGICAL PROCEDURES; PHOTOCHEMOTHERAPY; SYNDROME;

EID: 18844443731     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icu.0000161228.21797.d9     Document Type: Review

References (57)

1. Woods AC, Wahlen HE. The probable role of benign histoplasmosis in the etiology of granulomatous uveitis. Am J Ophthalmol 1960; 49:205-220.
2. Lewis ML, van Newkirk MR, Gass JDM. Follow-up study of presumed ocular histoplasmosis syndrome. Ophthalmology 1980; 87:390-399.
3. Smith RE, Ganley JP. An epidemiologic study of presumed ocular histoplasmosis. Trans Am Acad Ophthalmol Otolaryngol 1971; 75:994-1005.
4. Gass JDM, Wilkinson CP. Follow-up study of presumed ocular histoplasmosis. Trans Am Acad Ophthalmol Otolaryngol 1972; 76:672-694.
5. Olk RJ, Burgess DB, McCormick PA. Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome. Ophthalmology 1984; 91:1592-1602.
6. Kleiner RC, Tratner CM, Enger C, et al. Subfoveal neovascularization in the ocular histoplasmosis syndrome. Retina 1988; 8:225-229.
7. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. Arch Ophthalmol 1996; 114:677-688.
8. Callanan D, Fish E, Anand R. Reactivation of inflammatory lesions in ocular histoplasmosis. Arch Ophthalmol 1998; 116:470-474.
9. Wheat J. Histoplasmosis: experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore) 1997; 76:339-354.
10. Suttorp-Schulten MSA, Bollemeijer JG, Bos PJM, et al. Presumed ocular histoplasmosis in the Netherlands: an area without histoplasmosis. Br J Ophthalmol 1997; 81:7-11.
11. Reid JD, Sherer JH, Herbut PA, et al. Systemic histoplasmosis diagnosed before death and produced experimentally in guinea pigs. J Lab Clin Med 1942; 27:419-434.
12. Khalil MK. Histopathology of presumed ocular histoplasmosis. Am J Ophthalmol 1982; 94:369-376.
13. Spencer WH, Chan CC, Shen de F, et al. Detection of Histoplasma capsulatum DNA in lesions of chronic ocular histoplasmosis syndrome. Arch Ophthalmol 2003; 121:1551-1555.
14. Kunimoto DY, Kanitkar KD, Makar MS, eds. The Wills Eye Manual. 4th ed. Philadelphia; Lippincott Williams & Wilkins, 2004:430.
15. Saxe SJ, Grosniklaus HE, Lopez PF, et al. Ultrastructural features of surgically excised subretinal neovascular membranes in the ocular histoplasmosis syndrome. Arch Ophthalmol 1993; 111:88-95.
16. Specht CS, Mitchell KT, Bauman AE, et al. Ocular histoplasmosis with retinitis in a patient with acquired immune deficiency syndrome. Ophthalmology 1991; 98:1356-1359.
17. Ongkosuwito JV, Kortbeek LM, Van der Lelij A, et al. Aetiological study of the presumed ocular histoplasmosis syndrome in the Netherlands. Br J Ophthalmol 1999; 83:535-539.
18. Meredith TA, Smith RE, Braley RE, et al. The prevalence of HLA-b7 in presumed ocular histoplasmosis in patients with peripheral atrophic scars. Am J Ophthalmol 1978; 86:325-328.
19. Meredith TA, Smith RE, Duquesnoy RJ. Association of HLA-drw2 with presumed ocular histoplasmosis. Am J Ophthalmol 1980; 89:70-76.
20. Ongkosuwito JV, Tilanus MGJ, Van der Lelij A, et al. Amino acid residue 67 (isoleucine) of HLA-drb is associated with POHS. Invest Ophthalmol Vis Sci 2002; 45:1725-1729.
21. Dabil H, Kaplan HJ, Duffy BF, et al. Association of the HLA-dr15/HLA-dq6 haplotype with development of choroidal neovascular lesions in presumed ocular histoplasmosis syndrome. Hum Immunol 2003; 64:960-964.
22. Hirata AA, Terasaki PI. Cross-reaction between streptococcal m proteins and human transplantation antigens. Science 1970; 168:1095-1096.
23. Spraul CW, Grossniklaus HE. Characteristics of Drusen and Bruch's membrane in postmortem eyes with age-related macular degeneration. Arch Ophthalmol 1997; 115:267-273.
24. Giles CL, Falls HF. Further evaluation of amphotericin B therapy in presumptive histoplasmosis chorioretinitis. Am J Ophthalmol 1961; 51:588-598.
25. Makley TA, Long JW, Suie T. Therapy of chorioretinitis presumed to be caused by histoplasmosis. Int Ophthalmol Clin 1975; 15:181-196.
26. Schlaegel TF. Diagnosis and management of minimal recurrences of macular histoplasmosis. Int Ophthalmol Clin 1975; 15:167-179.
27. Onkhuma H, Ryan SJ. Vascular casts of experimental subretinal neovascularization in monkeys. Invest Ophthalmol Vis Sci 1983; 24:481-490.
28. Praia A, Hirakata A, McInnes J, et al. The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res 1993; 57:693-698.
29. Ciulla TA, Criswell MH, Danis RP, et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001; 119:399-404.
30. Martidis A, Miller DG, Ciulla TA, et al. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther 1999; 15:425-428.
31. Rechtman E, Allen VD, Danis RP, et al. Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 2003; 136:739-741.
32. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or heparin fragment. Science 1995; 230:1375-1378.
33. Clark AF, Mellon J, Li XY, et al. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci 1999; 40:2158-2162.
34. Schlaegel TF. Eye histoplasmosis. Ann Ophthalmol 1974; 11:1645-1654.
35. Brown GC, Brown MM, Sharma S, et al. Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis. Retina 2000; 20:331-337.
36. Macular Photocoagulation Study Group. Argon laser photocoagulation for ocular histoplasmosis: results of a randomized trial. Arch Ophthalmol 1983; 101:1347-1357.
37. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol 1987; 105:1499-1507.
38. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Arch Ophthalmol 1989; 107:344-352.
39. deJuan E, Machemer R. Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration. Am J Ophthalmol 1988; 105:25-29.
40. Thomas MA, Kaplan HJ. Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome. Am J Ophthalmol 1991; 111:1-7.
41. Berger AS, Kaplan HJ. Clinical experience with the surgical removal of subfoveal neovascular membranes. Ophthalmology 1992; 99:969-976.
42. Submacular Surgery Trials Research. Group: Surgical removal vs. observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular surgery trials (SST) group H trial: SST report no. 9. Arch Ophthalmol 2004; 122:1597-1612. This article presents the results of a large study of surgical treatment of POHS.
43. Submacular Surgery Trials Research Group. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: II. Quality-of-life findings from a randomized clinical trial: SST group H trial: SST report no. 10. Arch Ophthalmol 2004; 122:1616-1628.
44. Moshfeghi DM, Kaiser PK, Grossniklaus HE, et al. Clinicopathological study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003; 135:343-350.
45. Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology 1996; 103:427-438.
46. Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology 2002; 109:1499-1505.
47. Rosenfeld PJ, Saperstein DA, Bressler NM, et al. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study. Ophthalmology 2004; 111:1725-1733. This article presents very interesting and promising results of photodynamic therapy in POHS.
48. Busquets MA, Shah GK, Wickens J, et al. Ocular photodynamic therapy with vertoporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome. Retina 2003; 23:299-306.
49. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37:1929-1934.
50. Baffi J, Byrnes G, Chan CC, et al. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 2000; 41:3582-3589.
51. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120:338-346.
52. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology 2003; 110:979-986.
53. Gragoudas ES, Adamis AP, Cunningham ETJ, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-2816. This was the first large study to demonstrate a benefit of antiangiogenic therapy for the treatment of CNV. It did not address POHS specifically.
54. Heier JS, Sy JR, McCluskey ER, et al. RhuFab V2 in wet AMDL: 6 month continued improvement following multiple intravitreal injections. Invest Ophthalmol Vis Sci 2003; 44: ([E-abstract 972])
55. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (RhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46:726-733.
56. Csaky K. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls. Ophthalmology 2003; 110:879-881.
57. Spaide RF, Sorenson J, Maranan L. Combination photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110:1517-1525.